Detalhe da pesquisa
1.
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Breast Cancer Res Treat
; 199(2): 243-252, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944848
2.
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Breast Cancer Res Treat
; 196(3): 571-581, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36280642
3.
Molecular characterization of ESR1 variants in breast cancer.
Breast Cancer Res Treat
; 196(2): 279-289, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125660
4.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35230585
5.
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Breast Cancer Res Treat
; 188(1): 179-190, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33641083
6.
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Breast Cancer Res Treat
; 185(3): 863-868, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33400034
7.
The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling.
J Transl Med
; 19(1): 480, 2021 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838031
8.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171426
9.
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Oncologist
; 25(2): e214-e222, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043771
10.
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Breast Cancer Res Treat
; 184(2): 265-275, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32776290
11.
Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
Breast Cancer Res Treat
; 184(2): 543-558, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32876910
12.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509771
13.
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Breast Cancer Res Treat
; 178(2): 389-399, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31428908
14.
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.
Breast Cancer Res Treat
; 176(2): 407-417, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31006821
15.
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Future Oncol
; 15(17): 1951-1961, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30977385
16.
Luminal A Breast Cancer and Molecular Assays: A Review.
Oncologist
; 23(5): 556-565, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29472313
17.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
N Engl J Med
; 372(8): 724-34, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25693012
18.
Take care of your neighborhood.
Breast Cancer Res Treat
; 167(1): 225-234, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28900788
19.
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Lancet Oncol
; 18(1): 52-62, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27964843
20.
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Oncologist
; 22(5): 518-525, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28314836